These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30822809)

  • 1. Detection of Anti-Cardiolipin and Anti-β2glycoprotein I Antibodies Differs between Platforms without Influence on Association with Clinical Symptoms.
    Chayoua W; Kelchtermans H; Moore GW; Gris JC; Musial J; Wahl D; Zuily S; Gianniello F; Fontana P; Remijn J; Urbanus RT; de Laat B; Devreese KMJ
    Thromb Haemost; 2019 May; 119(5):797-806. PubMed ID: 30822809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-β2glycoprotein I antibody detection assays.
    Chayoua W; Kelchtermans H; Moore GW; Musiał J; Wahl D; de Laat B; Devreese KMJ
    J Thromb Haemost; 2018 Oct; 16(10):2016-2023. PubMed ID: 30079628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The (non-)sense of detecting anti-cardiolipin and anti-β2glycoprotein I IgM antibodies in the antiphospholipid syndrome.
    Chayoua W; Kelchtermans H; Gris JC; Moore GW; Musiał J; Wahl D; de Groot PG; de Laat B; Devreese KMJ
    J Thromb Haemost; 2020 Jan; 18(1):169-179. PubMed ID: 31519058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome.
    Persijn L; Decavele AS; Schouwers S; Devreese K
    Thromb Res; 2011 Dec; 128(6):565-9. PubMed ID: 21529896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome.
    Pericleous C; Ferreira I; Borghi O; Pregnolato F; McDonnell T; Garza-Garcia A; Driscoll P; Pierangeli S; Isenberg D; Ioannou Y; Giles I; Meroni PL; Rahman A
    PLoS One; 2016; 11(6):e0156407. PubMed ID: 27253369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome.
    De Craemer AS; Musial J; Devreese KM
    J Thromb Haemost; 2016 Sep; 14(9):1779-87. PubMed ID: 27314634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome.
    Mondejar R; González-Rodríguez C; Toyos-Sáenz de Miera FJ; Melguizo-Madrid E; Zohoury N; Mahler M; Romero Losquiño I; Fabiani F
    Clin Chim Acta; 2014 Apr; 431():174-8. PubMed ID: 24522162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical significance of antiphospholipid antibody measured by EliA anticardiolipin antibodies and anti-β2Glycoprotein I antibodies in antiphospholipid syndrome].
    Fujieda Y; Shida H; Oku K; Bohgaki T; Amengual O; Horita T; Yasuda S; Atsumi T
    Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(5):430-6. PubMed ID: 25744643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiphospholipid Antibody Testing for Anti-cardiolipin and Anti-β2 Glycoprotein I Antibodies Using Chemiluminescence-Based Panels.
    Favaloro EJ; Mohammed S; Vong R; Pasalic L
    Methods Mol Biol; 2023; 2663():297-314. PubMed ID: 37204719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.
    Iwaniec T; Kaczor MP; Celińska-Löwenhoff M; Polański S; Musiał J
    Thromb Res; 2017 May; 153():90-94. PubMed ID: 28363116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of three commercial ELISA kits for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome.
    Decavele AS; Schouwers S; Devreese KM
    Int J Lab Hematol; 2011 Feb; 33(1):97-108. PubMed ID: 20813022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements.
    Žigon P; Podovšovnik A; Ambrožič A; Tomšič M; Hočevar A; Gašperšič N; Rotar Ž; Praprotnik S; Šemrl SS; Čučnik S
    Clin Rheumatol; 2019 Feb; 38(2):371-378. PubMed ID: 30099654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticardiolipin antibody and anti-beta 2 glycoprotein I antibody assays.
    Raby A; Moffat K; Crowther M
    Methods Mol Biol; 2013; 992():387-405. PubMed ID: 23546732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory evaluation of anti-phospholipid syndrome: a preliminary prospective study of phosphatidylserine/prothrombin antibodies in an at-risk patient cohort.
    Heikal NM; Jaskowski TD; Malmberg E; Lakos G; Branch DW; Tebo AE
    Clin Exp Immunol; 2015 May; 180(2):218-26. PubMed ID: 25522978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward harmonized interpretation of anticardiolipin and anti-β2-glycoprotein I antibody detection for diagnosis of antiphospholipid syndrome using defined level intervals and likelihood ratios: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies.
    Vandevelde A; Gris JC; Moore GW; Musiał J; Zuily S; Wahl D; Devreese KMJ
    J Thromb Haemost; 2024 Aug; 22(8):2345-2362. PubMed ID: 38704123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There an Additional Value in Detecting Anticardiolipin and Anti-β2 glycoprotein I IgA Antibodies in the Antiphospholipid Syndrome?
    Chayoua W; Yin DM; Kelchtermans H; Moore GW; Gris JC; Musiał J; Zuily S; Ten Cate H; de Laat B; Devreese KMJ
    Thromb Haemost; 2020 Nov; 120(11):1557-1568. PubMed ID: 32696448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of anti-β2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and non-thrombotic patients.
    Despierres L; Beziane A; Kaplanski G; Granel B; Serratrice J; Cohen W; Bretelle F; Rossi P; Morange PE; Weiller PJ; Robert Harlé J; Bongrand P; Bardin N
    Rheumatology (Oxford); 2014 Jul; 53(7):1215-8. PubMed ID: 24599915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiphospholipid antibodies: evaluation of the thrombotic risk.
    Devreese KM
    Thromb Res; 2012 Oct; 130 Suppl 1():S37-40. PubMed ID: 23026657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome.
    Borghi MO; Beltagy A; Garrafa E; Curreli D; Cecchini G; Bodio C; Grossi C; Blengino S; Tincani A; Franceschini F; Andreoli L; Lazzaroni MG; Piantoni S; Masneri S; Crisafulli F; Brugnoni D; Muiesan ML; Salvetti M; Parati G; Torresani E; Mahler M; Heilbron F; Pregnolato F; Pengo M; Tedesco F; Pozzi N; Meroni PL
    Front Immunol; 2020; 11():584241. PubMed ID: 33178218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A unique antiphospholipid assay recognizing phospholipid mixture compared with criteria antiphospholipid immunoassays in lupus patients.
    Zuo Y; Willis R; Papalardo E; Petri M; Harris EN; Schleh A; DeCeulaer K; Smikle M; Vilá LM; Reveille JD; Alarcón GS; Gonzalez EB
    Lupus; 2017 May; 26(6):606-615. PubMed ID: 27753626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.